USD 243.84
(-0.72%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 2.39 Billion USD | 2.68% |
2022 | 2.61 Billion USD | 19.53% |
2021 | 2.18 Billion USD | 37.23% |
2020 | 1.59 Billion USD | 424.23% |
2019 | 303.82 Million USD | 912.74% |
2018 | 30 Million USD | 0.0% |
2017 | 30 Million USD | -80.0% |
2016 | 150 Million USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 2.68 Billion USD | 0.06% |
2024 Q3 | 2.49 Billion USD | 2.59% |
2024 Q2 | 2.42 Billion USD | -9.58% |
2023 Q4 | 2.68 Billion USD | 0.7% |
2023 Q3 | 2.66 Billion USD | 0.67% |
2023 Q2 | 2.64 Billion USD | 0.65% |
2023 Q1 | 2.62 Billion USD | 0.64% |
2023 FY | 2.68 Billion USD | 2.68% |
2022 Q3 | 2.59 Billion USD | 16.02% |
2022 Q2 | 2.23 Billion USD | 1.02% |
2022 Q1 | 2.21 Billion USD | 1.17% |
2022 FY | 2.61 Billion USD | 19.53% |
2022 Q4 | 2.61 Billion USD | 0.81% |
2021 Q3 | 1.91 Billion USD | 1.56% |
2021 FY | 2.18 Billion USD | 37.23% |
2021 Q4 | 2.18 Billion USD | 13.89% |
2021 Q2 | 1.88 Billion USD | 16.77% |
2021 Q1 | 1.61 Billion USD | 4.01% |
2020 Q2 | 1.29 Billion USD | 369.9% |
2020 Q4 | 1.55 Billion USD | 16.08% |
2020 FY | 1.59 Billion USD | 424.23% |
2020 Q1 | 275.78 Million USD | -0.13% |
2020 Q3 | 1.34 Billion USD | 3.42% |
2019 Q3 | 276.45 Million USD | -10.01% |
2019 Q1 | 312.3 Million USD | 941.0% |
2019 FY | 303.82 Million USD | 912.74% |
2019 Q4 | 276.13 Million USD | -0.12% |
2019 Q2 | 307.21 Million USD | -1.63% |
2018 Q2 | 30 Million USD | 0.0% |
2018 Q1 | 30 Million USD | 0.0% |
2018 FY | 30 Million USD | 0.0% |
2018 Q4 | 30 Million USD | 0.0% |
2018 Q3 | 30 Million USD | 0.0% |
2017 FY | 30 Million USD | -80.0% |
2017 Q4 | 30 Million USD | -80.0% |
2017 Q3 | 150 Million USD | 0.0% |
2017 Q2 | 150 Million USD | 0.0% |
2017 Q1 | 150 Million USD | 0.0% |
2016 Q4 | 150 Million USD | 0.0% |
2016 FY | 150 Million USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q2 | 150 Million USD | 0.0% |
2016 Q3 | 150 Million USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | -6463.431% |
Dynavax Technologies Corporation | 256.91 Million USD | -833.392% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -5674.592% |
Perrigo Company plc | 4.07 Billion USD | 41.13% |
Illumina, Inc. | 2.26 Billion USD | -6.013% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 93.132% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -239701.5% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 74.9% |
IQVIA Holdings Inc. | 14.23 Billion USD | 83.149% |
Heron Therapeutics, Inc. | 173.75 Million USD | -1280.129% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 11.28% |
Unity Biotechnology, Inc. | 26.99 Million USD | -8784.828% |
Waters Corporation | 2.35 Billion USD | -1.804% |
Biogen Inc. | 7.33 Billion USD | 67.321% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | -6193.342% |
Evolus, Inc. | 126.54 Million USD | -1794.975% |
Adicet Bio, Inc. | 17.7 Million USD | -13445.811% |
Cara Therapeutics, Inc. | 43.16 Million USD | -5455.204% |
bluebird bio, Inc. | 330.32 Million USD | -625.954% |
Esperion Therapeutics, Inc. | 540.94 Million USD | -343.299% |
FibroGen, Inc. | 170.45 Million USD | -1306.832% |
Agilent Technologies, Inc. | 2.73 Billion USD | 12.321% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -11382.419% |
Homology Medicines, Inc. | 44.05 Million USD | -5343.354% |
Geron Corporation | 85.89 Million USD | -2691.668% |
Amicus Therapeutics, Inc. | 445.05 Million USD | -438.808% |
Myriad Genetics, Inc. | 145 Million USD | -1553.803% |
Viking Therapeutics, Inc. | 1.26 Million USD | -190218.651% |
Intellia Therapeutics, Inc. | 115.34 Million USD | -1978.975% |
Zoetis Inc. | 6.8 Billion USD | 64.751% |
Abeona Therapeutics Inc. | 4.4 Million USD | -54375.579% |
Mettler-Toledo International Inc. | 2.16 Billion USD | -10.621% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -111.488% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -196.637% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | -6501.919% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -64.978% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | -4043.653% |
Verastem, Inc. | 41.55 Million USD | -5670.424% |
Nektar Therapeutics | 230.4 Million USD | -940.801% |
Axsome Therapeutics, Inc. | 186.37 Million USD | -1186.682% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -77909.597% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | -71.678% |
OPKO Health, Inc. | 326.56 Million USD | -634.317% |
Exelixis, Inc. | 189.94 Million USD | -1162.485% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | -459.761% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -1587989.404% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 138.4 Million USD | -1632.557% |
Imunon, Inc. | 1.13 Million USD | -210382.729% |
Blueprint Medicines Corporation | 774.12 Million USD | -209.772% |
Insmed Incorporated | 1.2 Billion USD | -99.172% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | -59.948% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -4107.93% |
TG Therapeutics, Inc. | 110.79 Million USD | -2064.371% |
Incyte Corporation | 38.28 Million USD | -6163.262% |
Emergent BioSolutions Inc. | 877.5 Million USD | -173.278% |